• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

小鼠肠系膜淋巴管中释放的胰高血糖素样肽-1:葡萄糖和脂肪的影响。

GLP-1 released to the mesenteric lymph duct in mice: effects of glucose and fat.

作者信息

Ohlsson Lena, Kohan Alison B, Tso Patrick, Ahrén Bo

机构信息

Department of Clinical Sciences Lund, Lund University, Lund, Sweden.

Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.

出版信息

Regul Pept. 2014 Feb 10;189:40-5. doi: 10.1016/j.regpep.2014.02.001. Epub 2014 Feb 28.

DOI:10.1016/j.regpep.2014.02.001
PMID:24583245
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4054822/
Abstract

Using a newly developed in vivo model measuring glucagon-like peptide-1 (GLP-1) in gut lymphatics in mice, we quantified GLP-1 secretion in vivo after glucose versus fat ingestion with and without concomitant DPP-4 inhibition. The mesenteric lymphatic duct was cannulated in anesthetized C57BL6/J mice and lymph was collected in 30 min intervals. Glucose or fat emulsion (Intralipid®) (0.03, 0.1 or 0.3 kcal) with or without DPP-4-inhibition (NVP DPP728; 10 μmol/kg) was administered by gastric gavage. Basal intact GLP-1 levels were 0.37±0.04 pmol/l (n=61) in lymph compared to 0.07±0.03 in plasma (n=6; P=0.04) and basal DPP-4 activity was 4.7±0.3 pmol/min/μl in lymph (n=23) compared to 22.3±0.9 pmol/min/μl in plasma (n=8; P<0.001). Lymph flow increased from 1.2±0.1 μl/min to 2.3±02μl/min at 30 min after glucose and fat administration, with no difference between type of challenge or dose (n=81). Lymph GLP-1 levels increased calorie-dependently after both glucose and fat but with different time courses in that glucose induced a transient increase which had returned to baseline after 90 min whereas the lipid induced a sustained increase which was still elevated above baseline after 210 min. Lymph GLP-1 appearance during 210 min was two to three-fold higher after glucose (7.4±2.3 fmol at 0.3 kcal) than after isocaloric fat (2.9±0.8 fmol at 0.3 kcal; P<0.001). The slope between caloric load and lymph GLP-1 appearance was, however, identical after glucose and fat. We conclude that lymph GLP-1 is higher than plasma GLP-1 whereas lymph DPP-4 activity is lower than plasma DPP-4 activity and that both glucose and fat clearly stimulate GLP-1 secretion calorie-dependently in vivo but with different time courses.

摘要

利用一种新开发的体内模型来测量小鼠肠道淋巴管中的胰高血糖素样肽-1(GLP-1),我们在有或没有同时进行二肽基肽酶-4(DPP-4)抑制的情况下,对摄入葡萄糖和脂肪后体内的GLP-1分泌进行了定量。在麻醉的C57BL6/J小鼠中插入肠系膜淋巴管,并每隔30分钟收集一次淋巴液。通过胃管给予含或不含DPP-4抑制剂(NVP DPP728;10 μmol/kg)的葡萄糖或脂肪乳剂(英脱利匹特®)(0.03、0.1或0.3千卡)。淋巴液中基础完整GLP-1水平为0.37±0.04 pmol/l(n=61),而血浆中为0.07±0.03(n=6;P=0.04);淋巴液中基础DPP-4活性为4.7±0.3 pmol/分钟/微升(n=23),而血浆中为22.3±0.9 pmol/分钟/微升(n=8;P<0.001)。给予葡萄糖和脂肪后30分钟,淋巴液流量从1.2±0.1微升/分钟增加到2.3±0.2微升/分钟,刺激类型或剂量之间无差异(n=81)。葡萄糖和脂肪摄入后,淋巴液中GLP-1水平均呈热量依赖性增加,但时间进程不同,葡萄糖引起短暂增加,90分钟后恢复到基线水平,而脂质引起持续增加,210分钟后仍高于基线水平。在210分钟内,葡萄糖摄入后淋巴液中GLP-1的出现量(0.3千卡时为7.4±2.3 fmol)比等热量脂肪摄入后(0.3千卡时为2.9±0.8 fmol;P<0.001)高两到三倍。然而,葡萄糖和脂肪摄入后热量负荷与淋巴液中GLP-1出现量之间的斜率相同。我们得出结论,淋巴液中GLP-1高于血浆中GLP-1,而淋巴液中DPP-4活性低于血浆中DPP-4活性,并且葡萄糖和脂肪在体内均能明显地以热量依赖性方式刺激GLP-1分泌,但时间进程不同。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c5c/4054822/7772dcc16d12/nihms-595624-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c5c/4054822/1b9e830f44e1/nihms-595624-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c5c/4054822/30b0d39d314a/nihms-595624-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c5c/4054822/7772dcc16d12/nihms-595624-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c5c/4054822/1b9e830f44e1/nihms-595624-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c5c/4054822/30b0d39d314a/nihms-595624-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c5c/4054822/7772dcc16d12/nihms-595624-f0003.jpg

相似文献

1
GLP-1 released to the mesenteric lymph duct in mice: effects of glucose and fat.小鼠肠系膜淋巴管中释放的胰高血糖素样肽-1:葡萄糖和脂肪的影响。
Regul Pept. 2014 Feb 10;189:40-5. doi: 10.1016/j.regpep.2014.02.001. Epub 2014 Feb 28.
2
Intestinal lymph as a readout of meal-induced GLP-1 release in an unrestrained rat model.在无束缚大鼠模型中,肠道淋巴液作为餐后诱导的胰高血糖素样肽-1释放的一种指标。
Am J Physiol Regul Integr Comp Physiol. 2018 May 1;314(5):R724-R733. doi: 10.1152/ajpregu.00120.2017. Epub 2018 Jan 17.
3
Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.通过抑制二肽基肽酶IV来保存活性肠促胰岛素激素可抑制犬餐后肠促胰岛素的分泌。
J Endocrinol. 2002 Feb;172(2):355-62. doi: 10.1677/joe.0.1720355.
4
Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels.高脂喂养的中性内肽酶缺陷小鼠血糖改善与二肽基肽酶-4(DPP-4)活性降低及活性胰高血糖素样肽-1(GLP-1)水平升高有关。
Diabetologia. 2017 Apr;60(4):701-708. doi: 10.1007/s00125-016-4172-4. Epub 2016 Dec 8.
5
Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects.二肽基肽酶-4 抑制剂治疗可使非糖尿病患者的血浆生物活性 GIP 水平升高幅度大于 GLP-1。
Mol Metab. 2016 Dec 31;6(2):226-231. doi: 10.1016/j.molmet.2016.12.009. eCollection 2017 Feb.
6
Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.二肽基肽酶 IV 抑制对健康男性脂肪引起的血糖、肠激素、甘油三酯、能量消耗和能量摄入反应的影响。
Am J Physiol Endocrinol Metab. 2014 Nov 1;307(9):E830-7. doi: 10.1152/ajpendo.00370.2014. Epub 2014 Sep 16.
7
Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.长期抑制二肽基肽酶-IV对高脂饮食喂养小鼠身体组成和葡萄糖耐量的影响。
Life Sci. 2009 Jun 19;84(25-26):876-81. doi: 10.1016/j.lfs.2009.03.022. Epub 2009 Apr 7.
8
Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.α-葡萄糖苷酶抑制剂伏格列波糖的长期给药通过增加ob/ob小鼠中活性胰高血糖素样肽-1的分泌并降低二肽基肽酶-4的活性来提高其水平。
J Pharmacol Exp Ther. 2009 May;329(2):669-76. doi: 10.1124/jpet.108.148056. Epub 2009 Feb 10.
9
Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.在 2 型糖尿病患者中外源性给予二甲双胍可增加血清胰高血糖素样肽-1 浓度并增强降血糖作用。
Metabolism. 2011 Jan;60(1):52-6. doi: 10.1016/j.metabol.2010.01.001. Epub 2010 Feb 11.
10
Stimulation of incretin secretion by dietary lipid: is it dose dependent?膳食脂质对肠促胰岛素分泌的刺激作用:是否存在剂量依赖性?
Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G299-305. doi: 10.1152/ajpgi.90601.2008. Epub 2009 Jun 11.

引用本文的文献

1
Transport functions of intestinal lymphatic vessels.肠道淋巴管的运输功能。
Nat Rev Gastroenterol Hepatol. 2025 Feb;22(2):127-145. doi: 10.1038/s41575-024-00996-z. Epub 2024 Nov 4.
2
Intestinal Lymph Collection via Cannulation of the Mesenteric Lymphatic Duct in Mice.经肠系膜淋巴管插管收集肠淋巴液在小鼠中的应用。
J Surg Res. 2021 Apr;260:399-408. doi: 10.1016/j.jss.2020.11.004. Epub 2020 Nov 28.
3
Neuropods.神经足。

本文引用的文献

1
High fat and high cholesterol diet induces DPP-IV activity in intestinal lymph.
J Oleo Sci. 2013;62(4):201-5. doi: 10.5650/jos.62.201.
2
Glucose-lowering effect of the DPP-4 inhibitor sitagliptin after glucose and non-glucose macronutrient ingestion in non-diabetic subjects.在非糖尿病受试者中,DPP-4 抑制剂西他列汀在摄入葡萄糖和非葡萄糖宏量营养素后的降血糖作用。
Diabetes Obes Metab. 2013 Jun;15(6):531-7. doi: 10.1111/dom.12062. Epub 2013 Feb 7.
3
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.GLP-1 受体激动剂用于 2 型糖尿病的个体化治疗。
Cell Mol Gastroenterol Hepatol. 2019;7(4):739-747. doi: 10.1016/j.jcmgh.2019.01.006. Epub 2019 Jan 30.
4
Lymphatic Vessel Network Structure and Physiology.淋巴管网络结构和生理学。
Compr Physiol. 2018 Dec 13;9(1):207-299. doi: 10.1002/cphy.c180015.
5
The Gut-Brain Axis, the Human Gut Microbiota and Their Integration in the Development of Obesity.肠-脑轴、人类肠道微生物群及其在肥胖症发展中的整合
Front Physiol. 2018 Jul 12;9:900. doi: 10.3389/fphys.2018.00900. eCollection 2018.
6
Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2.胰高血糖素原衍生肽胰高血糖素样肽 1 和胰高血糖素样肽 2 对肠道脂质和脂蛋白代谢的调节作用。
Curr Opin Lipidol. 2018 Apr;29(2):95-103. doi: 10.1097/MOL.0000000000000495.
7
Anxiety, Depression, and the Microbiome: A Role for Gut Peptides.焦虑、抑郁与微生物组:肠道肽的作用
Neurotherapeutics. 2018 Jan;15(1):36-59. doi: 10.1007/s13311-017-0585-0.
8
Discovery of 5-methyl-2-(4-((4-(methylsulfonyl)benzyl)oxy)phenyl)-4-(piperazin-1-yl)pyrimidine derivatives as novel GRP119 agonists for the treatment of diabetes and obesity.发现 5-甲基-2-(4-((4-(甲磺酰基)苄基)氧基)苯基)-4-(哌嗪-1-基)嘧啶衍生物作为新型 GRP119 激动剂用于治疗糖尿病和肥胖症。
Mol Divers. 2017 Aug;21(3):637-654. doi: 10.1007/s11030-017-9755-6. Epub 2017 Jun 27.
9
Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.胃饥饿素、胆囊收缩素、胰高血糖素样肽-1和酪酪肽(3-36):健康、肥胖及胃旁路术后进食与血糖方面的分泌调控及生理作用
Physiol Rev. 2017 Jan;97(1):411-463. doi: 10.1152/physrev.00031.2014.
10
Long-Term Catheterization of the Intestinal Lymph Trunk and Collection of Lymph in Neonatal Pigs.新生猪肠淋巴干的长期插管及淋巴采集
J Vis Exp. 2016 Mar 5(109):53457. doi: 10.3791/53457.
Nat Rev Endocrinol. 2012 Dec;8(12):728-42. doi: 10.1038/nrendo.2012.140. Epub 2012 Sep 4.
4
Synergism by individual macronutrients explains the marked early GLP-1 and islet hormone responses to mixed meal challenge in mice.单一宏量营养素的协同作用解释了小鼠对混合餐刺激的显著早期胰高血糖素样肽-1和胰岛激素反应。
Regul Pept. 2012 Oct 10;178(1-3):29-35. doi: 10.1016/j.regpep.2012.06.004. Epub 2012 Jun 28.
5
Meal-contingent intestinal lymph sampling from awake, unrestrained rats.清醒、未束缚大鼠的餐相关肠淋巴采样。
Am J Physiol Regul Integr Comp Physiol. 2012 Jun 15;302(12):R1365-71. doi: 10.1152/ajpregu.00497.2011. Epub 2012 Apr 18.
6
Nutrient detection by incretin hormone secreting cells.肠促胰岛素分泌细胞的营养物质检测。
Physiol Behav. 2012 Jun 6;106(3):387-93. doi: 10.1016/j.physbeh.2011.12.001. Epub 2011 Dec 13.
7
The future of incretin-based therapy: novel avenues--novel targets.基于肠促胰岛素治疗的未来:新途径-新靶点。
Diabetes Obes Metab. 2011 Oct;13 Suppl 1:158-66. doi: 10.1111/j.1463-1326.2011.01457.x.
8
Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans.口服和静脉给予脂肪对人肠降血糖素激素和胰岛素反应的影响。
J Clin Endocrinol Metab. 2011 Aug;96(8):2519-24. doi: 10.1210/jc.2011-0266. Epub 2011 May 18.
9
Using the lymph fistula rat model to study incretin secretion.利用淋巴瘘大鼠模型研究肠促胰岛素分泌。
Vitam Horm. 2010;84:221-49. doi: 10.1016/B978-0-12-381517-0.00008-4.
10
Incretin hormone secretion over the day.全天的肠降血糖素激素分泌。
Vitam Horm. 2010;84:203-20. doi: 10.1016/B978-0-12-381517-0.00007-2.